D Richard Lachno

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi request reprint Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics
    D Richard Lachno
    Eli Lilly and Company, Windlesham, UK
    J Alzheimers Dis 32:905-18. 2012
  2. ncbi request reprint Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-β of Peptides in Cerebrospinal Fluid Specimens from Alzheimer’s Disease Studies
    D Richard Lachno
    Lilly Research Centre, Windlesham, UK
    J Alzheimers Dis 45:527-42. 2015
  3. doi request reprint Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab
    D Richard Lachno
    Eli Lilly and Company, Windlesham, UK
    J Alzheimers Dis 34:897-910. 2013
  4. doi request reprint Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies
    D Richard Lachno
    Eli Lilly and Company, Windlesham, UK
    J Alzheimers Dis 26:531-41. 2011
  5. ncbi request reprint Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Cardiovasc Pharmacol 49:167-73. 2007
  6. doi request reprint The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur J Clin Pharmacol 66:127-35. 2010
  7. doi request reprint Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine
    Alonso Montoya
    Lilly Research Laboratories, Madrid, Spain
    J Child Neurol 26:31-6. 2011

Collaborators

Detail Information

Publications7

  1. doi request reprint Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics
    D Richard Lachno
    Eli Lilly and Company, Windlesham, UK
    J Alzheimers Dis 32:905-18. 2012
    ..In conclusion, the INNO-BIA plasma assay was successfully validated and qualified for use in clinical research...
  2. ncbi request reprint Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-β of Peptides in Cerebrospinal Fluid Specimens from Alzheimer’s Disease Studies
    D Richard Lachno
    Lilly Research Centre, Windlesham, UK
    J Alzheimers Dis 45:527-42. 2015
    ..They have proved to be robust and reliable tools for pharmacodynamic evaluations of investigational AD therapeutics in clinical trials...
  3. doi request reprint Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab
    D Richard Lachno
    Eli Lilly and Company, Windlesham, UK
    J Alzheimers Dis 34:897-910. 2013
    ..The clinical experience with these assays post validation has shown them to be robust and reliable...
  4. doi request reprint Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies
    D Richard Lachno
    Eli Lilly and Company, Windlesham, UK
    J Alzheimers Dis 26:531-41. 2011
    ..No effect of treatment with semagacestat or solanezumab was observed in response to three months of drug administration...
  5. ncbi request reprint Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects
    Joseph A Jakubowski
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Cardiovasc Pharmacol 49:167-73. 2007
    ..Within the limitations of the study, prasugrel was found to be well tolerated when dosed as LD followed by MD in the presence of ASA and provided greater platelet inhibition than ASA alone...
  6. doi request reprint The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects
    David S Small
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur J Clin Pharmacol 66:127-35. 2010
    ..We compared prasugrel pharmacokinetics, pharmacodynamics, and tolerability in healthy Chinese, Japanese, Korean and Caucasian subjects...
  7. doi request reprint Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine
    Alonso Montoya
    Lilly Research Laboratories, Madrid, Spain
    J Child Neurol 26:31-6. 2011
    ..It remains a possibility that this ratio might have value to facilitate personalized atomoxetine pharmacotherapy in ADHD patients...